PMID- 20965927
OWN - NLM
STAT- MEDLINE
DCOM- 20110111
LR  - 20191210
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
VI  - 65
IP  - 12
DP  - 2010 Dec
TI  - Pneumococcal conjugate vaccine-induced regulatory T cells suppress the 
      development of allergic airways disease.
PG  - 1053-60
LID - 10.1136/thx.2009.131508 [doi]
AB  - BACKGROUND: Infections with some bacteria, including Streptococcus pneumoniae, 
      have been associated with a reduced incidence of asthma. Components of S 
      pneumoniae may have the potential to modulate allergic inflammatory responses and 
      suppress the development of asthma. OBJECTIVES: To determine if human S 
      pneumoniae vaccines have the potential to suppress asthma by elucidating their 
      effect on allergic airways disease (AAD) in mouse models. METHODS: AAD was 
      induced in BALB/c mice by intraperitoneal sensitisation and intranasal challenge 
      with ovalbumin. Pneumococcal conjugate or polysaccharide vaccines were 
      administered at the time of sensitisation or during established AAD. Hallmark 
      features of AAD were assessed. Levels of regulatory T cells (Tregs) were 
      quantified by fluorescence-activated cell sorting, and their immunoregulatory 
      capacity was assessed using proliferation assays and anti-CD25 antibody 
      treatment. RESULTS: Intranasal administration of the conjugate vaccine, but not 
      the polysaccharide vaccine, suppressed the hallmark features of AAD, including: 
      eosinophilic and T helper 2-mediated inflammation; airway hyper-responsiveness; 
      circulating immunoglobulin E (IgE) levels; and mucus hypersecretion. 
      Intramuscular administration of the conjugate vaccine had limited protective 
      effects. The conjugate vaccine increased Tregs in the lung-draining lymph nodes, 
      lung and spleen. Furthermore, conjugate vaccine-induced Tregs had an enhanced 
      capacity to suppress T effector responses. Anti-CD25 administration reversed the 
      suppressive effects of the conjugate vaccine. CONCLUSIONS: A currently available 
      human conjugate vaccine suppresses the hallmark features of AAD through the 
      induction of Tregs. Thus targeted administration may provide a novel 
      immunoregulatory treatment for asthma.
FAU - Thorburn, Alison N
AU  - Thorburn AN
AD  - Centre for Asthma and Respiratory Disease and Hunter Medical Research Institute 
      and The University of Newcastle, Newcastle, New South Wales, Australia.
FAU - O'Sullivan, Brendan J
AU  - O'Sullivan BJ
FAU - Thomas, Ranjeny
AU  - Thomas R
FAU - Kumar, Rakesh K
AU  - Kumar RK
FAU - Foster, Paul S
AU  - Foster PS
FAU - Gibson, Peter G
AU  - Gibson PG
FAU - Hansbro, Philip M
AU  - Hansbro PM
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101021
PL  - England
TA  - Thorax
JT  - Thorax
JID - 0417353
RN  - 0 (CD2 Antigens)
RN  - 0 (Pneumococcal Vaccines)
RN  - 0 (Vaccines, Conjugate)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Asthma/immunology/*prevention & control
MH  - CD2 Antigens/immunology
MH  - Disease Models, Animal
MH  - Female
MH  - Immune Tolerance
MH  - Injections, Intramuscular
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Ovalbumin/immunology
MH  - Pneumococcal Vaccines/*immunology
MH  - T-Lymphocytes, Regulatory/*immunology
MH  - Th2 Cells/immunology
MH  - Vaccines, Conjugate/immunology
EDAT- 2010/10/23 06:00
MHDA- 2011/01/12 06:00
CRDT- 2010/10/23 06:00
PHST- 2010/10/23 06:00 [entrez]
PHST- 2010/10/23 06:00 [pubmed]
PHST- 2011/01/12 06:00 [medline]
AID - thx.2009.131508 [pii]
AID - 10.1136/thx.2009.131508 [doi]
PST - ppublish
SO  - Thorax. 2010 Dec;65(12):1053-60. doi: 10.1136/thx.2009.131508. Epub 2010 Oct 21.